Sugi Predict

Sugi Predict / Compounds / SCHEMBL937028

SCHEMBL937028

SCHEMBL937028

Cc1cc(C(C)(C)C)c(O[Al](C)Oc2c(C(C)(C)C)cc(C)cc2C(C)(C)C)c(C(C)(C)C)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ ALDH1A1 P00352 3/20 0.46
▸ CA2 P00918 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ TYR P14679 1/20 0.46
▸ HSPA5 P11021 1/20 0.38
▸ CYP2D6 P10635 2/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ CYP2C9 P11712 2/20 0.37
▸ CYP2C19 P33261 2/20 0.37
▸ HIF1A Q16665 2/20 0.37
▸ HSD17B10 Q99714 1/20 0.33
▸ TSHR P16473 1/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.31
▸ CYP1A2 P05177 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ ALOX15 P16050 1/20 0.31
▸ ATP2A2 P16615 1/20 0.31
▸ ATP2A3 Q93084 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL938331 0.87 SMN1; SMN2 (0.46) SMN1; SMN2ALDH1A1CA2POLBTYR
SCHEMBL77412 0.84 SMN1; SMN2 (0.48) SMN1; SMN2ALDH1A1CA2POLBTYR
SCHEMBL8859897 0.83 SMN1; SMN2 (0.43) SMN1; SMN2ALDH1A1CA2POLBTYR
SCHEMBL1304654 0.83 GABRA1 (0.34) SMN1; SMN2ALDH1A1POLBCYP3A4CYP2C9
SCHEMBL28424390 0.81 PTGDR2 (0.33) SMN1; SMN2ALDH1A1KDM4ECYP1A2MAPT
SCHEMBL585885 0.79 SMN1; SMN2 (0.43) SMN1; SMN2ALDH1A1CA2POLBTYR
SCHEMBL585935 0.78 SMN1; SMN2 (0.42) SMN1; SMN2ALDH1A1CA2POLBTYR
SCHEMBL937756 0.78 SMN1; SMN2 (0.42) SMN1; SMN2ALDH1A1CA2POLBTYR
SCHEMBL30023069 0.78 SMN1; SMN2 (0.42) SMN1; SMN2ALDH1A1CA2POLBTYR
SCHEMBL585869 0.78 SMN1; SMN2 (0.42) SMN1; SMN2ALDH1A1CA2POLBTYR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120192444-A (Meth) acrylic ester (co) polymerization method based on (non) biomass source under synergistic regulation of thiourea anions containing S negative nucleophilic centers and Lewis acid without hydrogen bond participation 青岛大学 2025-06-24 — — CN claimed
CN-117362482-A Polymerization catalyst composition, method for preparing block copolymer and application thereof 中国石油化工股份有限公司 2024-01-09 — — CN claimed
CN-115260353-B Acrylic ester polymerization reaction method based on synergistic regulation and control of hydrogen bond and Lewis acid 青岛大学 2023-08-15 — — CN claimed
CN-115260353-A Acrylate polymerization reaction method based on cooperative regulation and control of hydrogen bond and Lewis acid 青岛大学 2022-11-01 — — CN claimed
CN-114901645-A Triazine UV absorbent and preparation method thereof 巴斯夫欧洲公司 2022-08-12 — — CN claimed
CN-113736001-B Application of Lewis base, sorbate polymer and derivative thereof 吉林大学 2022-07-01 — — CN claimed
CN-108264593-B Active polymerization method of hindered L ewis acid-base pair-F L P catalyzed vinyl polar monomer 吉林大学 2020-08-04 — — CN claimed
EP-2099833-B1 CATALYST ACTIVATORS, PROCESSES FOR MAKING SAME, AND USE THEREOF IN CATALYSTS AND POLYMERIZATION OF OLEFINS ALBEMARLE CORP (US) 2015-11-11 — — EP claimed
US-8501655-B2 thermal stability, high catalyst activity; Bronsted acidic cation such as ionic compound formed from pentafluorophenol and dimethylaniline, and aluminate anion chemically bonded to a carrier ALBEMARLE CORPORATION (US) 2013-08-06 — — US claimed
US-7928172-B2 Catalyst activators, processes for making same, and use thereof in catalysts and polymerization of olefins ALBEMARLE CORPORATION (US) 2011-04-19 — — US claimed
US-20100093958-A1 CATALYST ACTIVATORS, PROCESSES FOR MAKING SAME, AND USE THEREOF IN CATALYSTS AND POLYMERIZATION OF OLEFINS W. R. GRACE & CO.-CONN. 2010-04-15 — — US claimed
US-20100029470-A1 Catalyst Activators, Processes for Making Same, And Use Thereof In Catalysts And Polymerization Of Olefins ALBENARLE CORPORATION (US) 2010-02-04 — — US claimed
EP-2099833-A2 CATALYST ACTIVATORS, PROCESSES FOR MAKING SAME, AND USE THEREOF IN CATALYSTS AND POLYMERIZATION OF OLEFINS Albermarle Corporation (US) 2009-09-16 — — EP claimed
WO-2008036594-A2 CATALYST ACTIVATORS, PROCESSES FOR MAKING SAME, AND USE THEREOF IN CATALYSTS AND POLYMERIZATION OF OLEFINS ALBEMARLE CORPORATION (US) 2008-03-27 — — WO claimed
US-20260078117-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS INC (US) 2026-03-19 — — US disclosed
CN-120192444-A (Meth) acrylic ester (co) polymerization method based on (non) biomass source under synergistic regulation of thiourea anions containing S negative nucleophilic centers and Lewis acid without hydrogen bond participation 青岛大学 2025-06-24 — — CN disclosed
EP-3892652-B1 POLYBUTADIENE, POLYBUTADIENE PRODUCTION METHOD, POLYBUTADIENE COMPOSITION, TIRE, AND RESIN MEMBER BRIDGESTONE CORP (JP) 2025-04-30 — — EP disclosed
EP-0686649-A1 PROPYLENE BLOCK COPOLYMER, PROCESS FOR PRODUCING THE SAME, AND MODIFIED COPOLYMER PRODUCED THEREFROM IDEMITSU KOSAN COMPANY LIMITED (JP) 1995-12-13 — — EP disclosed
EP-0675138-A1 POLYMERIZATION CATALYST AND PROCESS FOR PRODUCING POLYMER USING THE SAME IDEMITSU KOSAN COMPANY LIMITED (JP) 1995-10-04 — — EP disclosed
EP-0667359-A1 OLEFIN COPOLYMERS AND PROCESS FOR PRODUCING THE SAME IDEMITSU KOSAN COMPANY LIMITED (JP) 1995-08-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260078117-A1 COMPOUNDS AND METHODS OF USE NR3C2, ADRA1A, CNR1 SMN1; SMN2 1645/4885ALDH1A1 100/4885CA2 369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.